Abstract: A composition comprising a high purity cannabinoid, an acid, and a pharmaceutically-acceptable solvent achieves room temperature stability for over 24 months. The acid improves the stability of the composition and the solvent enhances the solubility of the acid, thereby allowing the acid to have an improved stabilizing effect on the highly pure cannabinoid. Preferably, the solvent is an alcohol and, more preferably, the composition contains an oil. A method for making the composition includes combining the cannabinoid and the solvent and evaporating a portion of the solvent, along with adding an acid to the composition, before, during, or after the evaporating step. A method for making and storing the composition includes storing the composition in a manner adapted to maintain its stability. Pharmaceutical dosage forms include a formulated composition, such as having the oil. A method of treating a subject comprises administering to the subject the dosage form.

Abstract: A composition comprising a high purity cannabinoid, an acid, and a pharmaceutically-acceptable solvent achieves room temperature stability for over 24 months. The acid improves the stability of the composition and the solvent enhances the solubility of the acid, thereby allowing the acid to have an improved stabilizing effect on the highly pure cannabinoid. Preferably, the solvent is an alcohol and, more preferably, the composition contains an oil. A method for making the composition includes combining the cannabinoid and the solvent and evaporating a portion of the solvent, along with adding an acid to the composition, before, during, or after the evaporating step. A method for making and storing the composition includes storing the composition in a manner adapted to maintain its stability. Pharmaceutical dosage forms include a formulated composition, such as having the oil. A method of treating a subject comprises administering to the subject the dosage form.

Abstract: A composition comprising a high purity cannabinoid, an acid, and a pharmaceutically-acceptable solvent achieves room temperature stability for over 24 months. The acid improves the stability of the composition and the solvent enhances the solubility of the acid, thereby allowing the acid to have an improved stabilizing effect on the highly pure cannabinoid. Preferably, the solvent is an alcohol and, more preferably, the composition contains an oil. A method for making the composition includes combining the cannabinoid and the solvent and evaporating a portion of the solvent, along with adding an acid to the composition, before, during, or after the evaporating step. A method for making and storing the composition includes storing the composition in a manner adapted to maintain its stability. Pharmaceutical dosage forms include a formulated composition, such as having the oil. A method of treating a subject comprises administering to the subject the dosage form.

Abstract: A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be ?8 tetrahydrocannabinol, (?)-?9-trans-tetrahydrocannabinol or a side chain alkyl derivative of either compound, the solvent may be an oil or C1-C4 alcohol (e.g. sesame oil or ethanol), and the acid may be an organic acid or a mineral acid.

Abstract: A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be ?8 tetrahydrocannabinol, (?)-?9-trans-tetrahydrocannabinol or a side chain alkyl derivative of either compound, the solvent may be an oil or C1-C4 alcohol (e.g. sesame oil or ethanol), and the acid may be an organic acid or a mineral acid.

Abstract: A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be ?8 tetrahydrocannabinol, (?)-?9-trans-tetrahydrocannabinol or a side chain alkyl derivative of either compound, the solvent may be an oil or C1-C4 alcohol (e.g. sesame oil or ethanol), and the acid may be an organic acid or a mineral acid.

Abstract: A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be ?8 tetrahydrocannabinol, (?)-?9-trans-tetrahydrocannabinol or a side chain alkyl derivative of either compound, the solvent may be an oil or C1-C4 alcohol (e.g. sesame oil or ethanol), and the acid may be an organic acid or a mineral acid.

Abstract: A composition comprising a high purity cannabinoid, an acid, and a pharmaceutically-acceptable solvent achieves room temperature stability for over 24 months. The acid improves the stability of the composition and the solvent enhances the solubility of the acid, thereby allowing the acid to have an improved stabilizing effect on the highly pure cannabinoid. Preferably, the solvent is an alcohol and, more preferably, the composition contains an oil. A method for making the composition includes combining the cannabinoid and the solvent and evaporating a portion of the solvent, along with adding an acid to the composition, before, during, or after the evaporating step. A method for making and storing the composition includes storing the composition in a manner adapted to maintain its stability. Pharmaceutical dosage forms include a formulated composition, such as having the oil. A method of treating a subject comprises administering to the subject the dosage form.

Abstract: A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be ?8 tetrahydrocannabinol, (?)-?9-trans-tetrahydrocannabinol or a side chain alkyl derivative of either compound, the solvent may be an oil or C1-C4 alcohol (e.g. sesame oil or ethanol), and the acid may be an organic acid or a mineral acid.

Abstract: A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be ?8 tetrahydrocannabinol, (?)-?9-trans-tetrahydrocannabinol or a side chain alkyl derivative of either compound, the solvent may be an oil or C1-C4 alcohol (e.g. sesame oil or ethanol), and the acid may be an organic acid or a mineral acid.

Abstract: A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be ?8 tetrahydrocannabinol, (?)-?9-trans-tetrahydrocannabinol or a side chain alkyl derivative of either compound, the solvent may be an oil or C1-C4 alcohol (e.g. sesame oil or ethanol), and the acid may be an organic acid or a mineral acid.

Abstract: A multi-purpose gown comprising a front and a back defining a body portion having arm openings and a neck opening. The front portion is dividable into a plurality of segments by various openings releasably closable by a plurality of fasteners. A strap extends in the front of the gown from the top to the bottom of the gown. The strap includes fasteners for attachment to fasteners arranged on the front portions of the gown. Alternatively, the gown may embody a front having overlapping panels that cover the abdomen, wherein each panel has an upper segment adapted to cover a breast, side, and front shoulder region of the wearer. The upper segments are releasably joined to the back by fasteners at the shoulder edges of the gown. When either one of these segments is in its open position, portions of the patient's chest, front shoulder and side torso regions are exposed, while minimizing body exposure and maintaining structural stability of the gown.

Abstract: An automatic chemical analyzer for the analysis of physiological samples. A scanning monochromatic spectrophotometer may be used to determine the absorbance of the sample under control of a central processing unit. Outputs from one of several ion selective electrodes may also be selected by the system. The information obtained from the measurements is stored in memory or ouputted to output devices. Information about the test parameters may be read from an optical bar code associated with the test kit for the particular chemical analysis.

Abstract: An in-line fluid warmer for heating parenteral fluids, particularly blood, supplied from a fluid container through a flexible supply conduit. The fluid warmer includes a box-like enclosure containing a heated plate having a sinuously-shaped groove configured to accept and hold a length of the supply conduit in heat transfer relationship with the plate. A pair of temperature sensors monitor the actual temperature of the plate. One of the temperature sensors controls a voltage controlled oscillator, while the other is used to determine maximum permissible plate temperature. The voltage controlled oscillator supplies proportional control to the heated plate up to a predetermined temperature of 37.degree. C. for warming blood.

Abstract: A reverse-phase chromatographic packing having a carbon content of over 20% by weight is prepared by hydrolyzing silica gel with a mixture of sulfuric and nitric acid, washing the treated silica gel and drying it, reacting the hydrolyzed silica gel with an alkylchlorosilane, washing the product, and drying it all under conditions which maintain a moisture content in the silica.

Abstract: A new colorimeter blood analyzer having a capacity of simultaneously performing a specific blood test and reading the prothrombin time on a separate digital readout device. The program circuit module with appropriate calibration parameters which is self-referencing performs specific tests providing direct display of the desired blood constituent concentration. The analyzer provides an independent prothrombin well having a separate optical source for prothrombin time measurement providing direct display on an independent readout display. The analyzer also has a built-in digital readout quartz crystal timing device which can be operated when prothrombin time analysis is not conducted. The entire analyzer is contained in a compact console which includes controlled incubated storage for blood test samples together with insertion cavities for both constituent concentration and prothrombin time analysis.